X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs DIVIS LABORATORIES - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH DIVIS LABORATORIES STERLING BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x -0.4 35.4 - View Chart
P/BV x 0.0 6.9 0.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
DIVIS LABORATORIES
Mar-18
STERLING BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs111,142 0.9%   
Low Rs3533 0.6%   
Sales per share (Unadj.) Rs26.8146.6 18.3%  
Earnings per share (Unadj.) Rs-15.033.0 -45.3%  
Cash flow per share (Unadj.) Rs-5.538.4 -14.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs54.9222.8 24.6%  
Shares outstanding (eoy) m267.87265.47 100.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.7 4.5%   
Avg P/E ratio x-0.525.3 -1.8%  
P/CF ratio (eoy) x-1.321.8 -5.8%  
Price / Book Value ratio x0.13.8 3.4%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m1,862222,318 0.8%   
No. of employees `0001.410.8 12.6%   
Total wages/salary Rs m5474,561 12.0%   
Avg. sales/employee Rs Th5,303.33,616.0 146.7%   
Avg. wages/employee Rs Th403.8423.8 95.3%   
Avg. net profit/employee Rs Th-2,959.0814.9 -363.1%   
INCOME DATA
Net Sales Rs m7,18138,915 18.5%  
Other income Rs m431,134 3.8%   
Total revenues Rs m7,22340,049 18.0%   
Gross profit Rs m94712,617 7.5%  
Depreciation Rs m2,5431,425 178.5%   
Interest Rs m4,37713 32,910.5%   
Profit before tax Rs m-5,93112,313 -48.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9243,543 -54.3%   
Profit after tax Rs m-4,0078,770 -45.7%  
Gross profit margin %13.232.4 40.7%  
Effective tax rate %32.428.8 112.8%   
Net profit margin %-55.822.5 -247.6%  
BALANCE SHEET DATA
Current assets Rs m14,33545,351 31.6%   
Current liabilities Rs m49,8096,507 765.4%   
Net working cap to sales %-494.099.8 -494.9%  
Current ratio x0.37.0 4.1%  
Inventory Days Days403127 318.4%  
Debtors Days Days17195 179.4%  
Net fixed assets Rs m55,43221,160 262.0%   
Share capital Rs m268531 50.5%   
"Free" reserves Rs m13,93558,625 23.8%   
Net worth Rs m14,70159,156 24.9%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98867,832 109.1%  
Interest coverage x-0.4926.8 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.6 16.9%   
Return on assets %0.512.9 3.9%  
Return on equity %-27.314.8 -183.8%  
Return on capital %-6.420.8 -30.8%  
Exports to sales %25.90-   
Imports to sales %0.221.8 0.8%   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m128,485 0.1%   
Fx inflow Rs m1,86032,359 5.7%   
Fx outflow Rs m259,042 0.3%   
Net fx Rs m1,83523,317 7.9%   
CASH FLOW
From Operations Rs m1,7197,759 22.2%  
From Investments Rs m-3,148-4,783 65.8%  
From Financial Activity Rs m1,426-3,142 -45.4%  
Net Cashflow Rs m-3-166 2.0%  

Share Holding

Indian Promoters % 33.9 52.0 65.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 9.9 19.0 52.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.2 228.5%  
Shareholders   21,482 31,796 67.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare STERLING BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS